Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with severe burn injuries ≥ 40 % of TBSA (Total Body Surface Area)~* Thermal burn on symmetrical areas allowing grafting of 4 contiguous dermal substrates (cellularised LG002 or uncellularised LG002) on each area~* The patient himself, or his legal representative, must give his informed consent in writing~Exclusion Criteria:~* Anterior progressive serious illness (i.e severe hepatic insufficiency, immunodepression induced by corticotherapy or illness (AIDS))~* Metabolic disease~* Systemic infection or local burn infection~* Known allergy to collagen, streptomycin, Penicillin and/or bovine origine products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cellularised LG002 (Type: EXPERIMENTAL): Cellularised LG002
- UnCellularised LG002 (Type: EXPERIMENTAL): UnCellularised LG002

Based on this trial design, predict the completion outcome and termination type (if applicable).